Nelson Labs Celebrates 40 Years of Excellence in Science and Service
April 17, 2025
SALT LAKE CITY, UT, April 17, 2025 – Nelson Labs, a global leader in microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries, proudly recognizes its 40th anniversary. Founded in 1985 as a modest laboratory in the University of Utah’s Research Park, Nelson Labs has since grown into an expansive network of 12 locations across North America, Asia, and Europe.
Over the past four decades, Nelson Labs has continuously broadened its service offerings and global presence to meet the evolving needs of its customers while maintaining an unwavering commitment to quality and scientific expertise. Key milestones in Nelson Labs’ history include the 2017 addition of a state-of-the-art Extractables and Leachables laboratory in Belgium, which now serves as its European headquarters, and the 2021 acquisition of a US-based regulatory compliance advisory business. During this time, Nelson Labs has also expanded its pharmaceutical services, making strategic investments to enhance support for drug product manufacturers.
“In celebrating 40 Years of Science and Service, we reflect on our impact and the individuals who have contributed to this tremendous milestone,” stated Joe Shrawder, President of Nelson Labs. “Our continued success is the product of our exceptional scientists, loyal customers, and our teams’ dedication to our shared mission of Safeguarding Global Health.”
Looking ahead, Nelson Labs remains focused on scientific innovation, ongoing investments in its employees, and further enhancements of its infrastructure. As a trusted partner to top medical device and pharmaceutical manufacturers, Nelson Labs is committed to delivering excellence in laboratory testing and consulting solutions to help safely and effectively bring life-saving products to market around the world.
To see Nelson Labs’ impact firsthand, view this video showcasing its Salt Lake City headquarters.
For more information about Nelson Labs and its services, visit www.nelsonlabs.com.
Recent News
- Biolexis Therapeutics Advances Breakthrough GLP-1 and AMPK Programs into First-in-Human Clinical Trials
- Rebel Medicine Announces Series A Financing and Investigational New Drug (IND) Application Opening to Advance Non‑Opioid Pain Therapeutic into Clinical Development
- NUSANO STABLE ISOTOPE PROGRAM ENRICHES GADOLINIUM-160 TO 99.2% PURITY
- CancerVax Targets Liver Cancers to Further Showcase Flexibility of Its Universal Platform
- Seek Labs Unveils BioSeeker™
- Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)